U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H34O5
Molecular Weight 390.5131
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TREPROSTINIL

SMILES

[H][C@]12C[C@@H](O)[C@H](CC[C@@H](O)CCCCC)[C@@]1([H])CC3=C(C2)C(OCC(O)=O)=CC=C3

InChI

InChIKey=PAJMKGZZBBTTOY-ZFORQUDYSA-N
InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1

HIDE SMILES / InChI
Molecular Formula C23H34O5
Molecular Weight 390.5131
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412595/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515411/

Treprostinil (marketed under the trade names Remodulin for infusion) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in the arteries between the heart and lungs. PAH is characterized by symptoms of shortness of breath during physical exertion. The condition can ultimately lead to heart failure. Treprostinil is a potent oral antiplatelet agent. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed. Treprostinil had high affinity for the Prostaglandin D2 receptor (DP1), Prostaglandin E2 receptor EP2 subtype (EP2) and Prostaglandin D2 receptor (IP) receptors (Ki 4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, Prostaglandin F (FP) and thromboxane (TP) receptors. Treprostinil has demonstrated a unique effect on PPAR gamma, a transcription factor important in vascular pathogenesis as a mediator of proliferation, inflammation and apoptosis. Through a complementary, yet cyclic AMP-independent pathway, treprostinil activates PPARs, another mechanism that contributes to the anti-growth benefits of the prostacyclin class.

Originator

U.K. research team
5
Curator's Comment: By 1976, Vane and fellow researcher Salvador Moncada published the first paper on prostacyclin, in the scientific journal Nature. The collaboration produced a synthetic molecule which was given the name epoprostenol. But like native prostacyclin, the structure of the epoprostenol molecule proved to be unstable in solution, prone to rapid degradation. This presented a challenge for both in vitro experiments and clinical applications. To overcome this challenge, the research team that discovered prostacyclin was determined to continue the research in an attempt to build upon the success they had seen with the prototype molecule. The research team synthesized nearly 1,000 analogs.

Approval Year

2002
144
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 32.0 nM [Ki]
Agonist
2678
 4.4 nM [Ki]
Agonist
2678
 3.6 nM [Ki]
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
REMODULIN

Approved Use

Remodulin is a prostacyclin vasodilator indicated for: Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) (1.1) Patients who require transition from Flolan®, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2) 1.1 Pulmonary Arterial Hypertension Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) [see Clinical Studies (14.1)

Launch Date

2002
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.71 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24603117
0.5 mg 3 times / day multiple, oral
dose: 0.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
0.54 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24603117
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.53 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24603117
0.5 mg 3 times / day multiple, oral
dose: 0.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.46 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24603117
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.34 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24603117
0.5 mg 3 times / day multiple, oral
dose: 0.5 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.06 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24603117
0.5 mg single, oral
dose: 0.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TREPROSTINIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
9%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021272s020lbledt.pdf
TREPROSTINIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 3 times / day steady, subcutaneous
Overdose
Dose: 20 mg, 3 times / day
Route: subcutaneous
Route: steady
Dose: 20 mg, 3 times / day
Co-administed with::
chlorothiazide(500 mg)
lasix(40 mg)
coumadin(4 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19285625/
unhealthy, 10 years
n = 1
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 10 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19285625/
Disc. AE: Nausea, Blurred vision...
AEs leading to
discontinuation/dose reduction:
Nausea (1 patient)
Blurred vision (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19285625/
7.5 mg single, subcutaneous
Overdose
Dose: 7.5 mg
Route: subcutaneous
Route: single
Dose: 7.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29674328/
unhealthy, 29 years
n = 1
Health Status: unhealthy
Condition: group 1 pulmonary arterial hypertension
Age Group: 29 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/29674328/
Disc. AE: Circulatory collapse...
AEs leading to
discontinuation/dose reduction:
Circulatory collapse (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/29674328/
150 ug single, respiratory
Highest studied dose
Dose: 150 ug
Route: respiratory
Route: single
Dose: 150 ug
Sources:
https://pubmed.ncbi.nlm.nih.gov/33282202/
healthy, 30.3 years
n = 43
Health Status: healthy
Age Group: 30.3 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/33282202/
Other AEs: Cough, Throat irritation...
Other AEs:
Cough (26 patients)
Throat irritation (26 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33282202/
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
Disc. AE: Hypotension, Tachycardia...
AEs leading to
discontinuation/dose reduction:
Hypotension (1 patient)
Tachycardia (1 patient)
Arrhythmia ventricular (1 patient)
Dyspnea (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
36 ug 4 times / day steady, respiratory (max)
Recommended
Dose: 36 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 36 ug, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22917554/
unhealthy, 7.1 - 19.2 years
n = 29
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 7.1 - 19.2 years
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/22917554/
Disc. AE: Bronchospasm...
AEs leading to
discontinuation/dose reduction:
Bronchospasm (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22917554/
AEs

AEs

AESignificanceDosePopulation
Blurred vision 1 patient
Disc. AE
20 mg 3 times / day steady, subcutaneous
Overdose
Dose: 20 mg, 3 times / day
Route: subcutaneous
Route: steady
Dose: 20 mg, 3 times / day
Co-administed with::
chlorothiazide(500 mg)
lasix(40 mg)
coumadin(4 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19285625/
unhealthy, 10 years
n = 1
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 10 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19285625/
Nausea 1 patient
Disc. AE
20 mg 3 times / day steady, subcutaneous
Overdose
Dose: 20 mg, 3 times / day
Route: subcutaneous
Route: steady
Dose: 20 mg, 3 times / day
Co-administed with::
chlorothiazide(500 mg)
lasix(40 mg)
coumadin(4 mg)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19285625/
unhealthy, 10 years
n = 1
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 10 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19285625/
Circulatory collapse 1 patient
Disc. AE
7.5 mg single, subcutaneous
Overdose
Dose: 7.5 mg
Route: subcutaneous
Route: single
Dose: 7.5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29674328/
unhealthy, 29 years
n = 1
Health Status: unhealthy
Condition: group 1 pulmonary arterial hypertension
Age Group: 29 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/29674328/
Cough 26 patients
150 ug single, respiratory
Highest studied dose
Dose: 150 ug
Route: respiratory
Route: single
Dose: 150 ug
Sources:
https://pubmed.ncbi.nlm.nih.gov/33282202/
healthy, 30.3 years
n = 43
Health Status: healthy
Age Group: 30.3 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/33282202/
Throat irritation 26 patients
150 ug single, respiratory
Highest studied dose
Dose: 150 ug
Route: respiratory
Route: single
Dose: 150 ug
Sources:
https://pubmed.ncbi.nlm.nih.gov/33282202/
healthy, 30.3 years
n = 43
Health Status: healthy
Age Group: 30.3 years
Sex: M+F
Population Size: 43
Sources:
https://pubmed.ncbi.nlm.nih.gov/33282202/
Arrhythmia ventricular 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
Dyspnea 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
Hypotension 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
Tachycardia 1 patient
Disc. AE
100 mg single, subcutaneous (min)
Overdose
Dose: 100 mg
Route: subcutaneous
Route: single
Dose: 100 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/23662045/
Bronchospasm 3 patients
Disc. AE
36 ug 4 times / day steady, respiratory (max)
Recommended
Dose: 36 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 36 ug, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22917554/
unhealthy, 7.1 - 19.2 years
n = 29
Health Status: unhealthy
Condition: pulmonary hypertension
Age Group: 7.1 - 19.2 years
Sex: M+F
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/22917554/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inducer
781
substrate
1037

inducer
389
substrate
1217
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
693

CYP1A2
1054

CYP2A6
543

CYP2C19
991

CYP4A11
119
CYP1A2
701

CYP2B6
547

CYP2C19
293
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2C19
1553
 no
CYP2C9
1819
 no
CYP3A4
1925
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C8
693
 major
yes (co-administration study)
Comment: Treprostinil plasma AUC and Cmax increased approximately 2-fold when administered with gemfibrozil; Treprostinil AUC decreased by 30% when adminsitered with rifampin;
Page: 12,14
CYP2C9
1037
 minor
weak (co-administration study)
Comment: Treprostinil AUC decreased approximately 14%, no effect on Cmax when adminstered with fluconazole;
Page: 12,14
CYP1A2
1054
 no
CYP2A6
543
 no
CYP2C19
991
 no
CYP2D6
1217
 no
CYP3A4
1737
 no
CYP4A11
119
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:50861
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50861
ChemicalBook
CB32460050
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32460050
MolPort
MolPort-027-720-928
https://www.molport.com/shop/molecule-link/MolPort-027-720-928
ZINC
ZINC000003800475
http://zinc15.docking.org/substances/ZINC000003800475
PubMed

PubMed

TitleDatePubMed
Treprostinil sodium Pharmacia.
2002 Apr
Gateways to clinical trials.
2002 Dec
Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents.
2003 May 1
Gateways to clinical trials.
2003 Sep
Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers.
2004 Aug
Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
2004 Jan
Gateways to clinical trials.
2004 Jul-Aug
Gateways to clinical trials.
2004 Jun
Treprostinil for pulmonary hypertension.
2004 Mar
Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
2004 Mar
Gateways to clinical trials.
2004 Mar
Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.
2004 May
Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
2005 Apr
Gateways to clinical trials.
2005 Dec
Gateways to clinical trials.
2005 Jan-Feb
Gateways to clinical trials.
2005 Jun
Gateways to clinical trials.
2005 Sep
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.
2006 Feb
[The best of clinical cardiovascular pharmacology in 2005].
2006 Jan
Gateways to clinical trials.
2006 Jan-Feb
Gateways to clinical trials.
2006 Jul-Aug
Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
2006 Jun
Gateways to clinical trials.
2006 Mar
Gateways to clinical trials.
2006 Sep
The Role of PPARs in Lung Fibrosis.
2007
The role of peroxisome proliferator-activated receptors in pulmonary vascular disease.
2007
Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
2007 Mar 2
Gateways to clinical trials.
2007 Nov
IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues.
2007 Sep 7
Patient safety challenges in treprostinil therapy.
2008 Apr
Treatment of a nonhealing saphenous vein harvest graft with treprostinil sodium.
2008 Apr
Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
2008 Jan
A novel catheter system for totally implantable intravenous drug therapy: assessment of catheter function and patency with trepostinil therapy.
2008 Jan-Mar
Primary pulmonary hypertension as a manifestation of adult multi-system mitochondrial disorder.
2009 Apr 30
Inhaled treprostinil and pulmonary arterial hypertension.
2010 Dec 3
Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
2010 Jul 23
Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan.
2010 Jun
Gateways to clinical trials.
2010 May
The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results.
2010 Nov
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
2012 Jul 1
Patents

Patents

07384978
5
07417070
5
07544713
5
08232316
5
08242305
5
08252839
5
08350079
5
08410169
5
08497393
5
08524939
5
08536363
5
08658837
5
08748657
5
JPH0687749A
5

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Treprostinil is available in three different formulations and four different routes of administration: Remodulin® (treprostinil sodium, intravenous and subcutaneous administration), Tyvaso® (treprostinil sodium, inhaled administration), and Orenitram® (treprostinil diolamine, oral administration) for the treatment of pulmonary arterial hypertension (PAH). https://www.ncbi.nlm.nih.gov/pubmed/?term=27286723
1.25 ng/kg/min (initial dose for continuous infusion, dosage should be chronically adjusted depending on clinical response)
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: Treprostinil (0.15 - 15 ng/ml) slightly increased contractile dynamics of cardiomyocytes at clinically relevant concentrations.
Treprostinil (0.15 - 15 ng/ml) rat cardiomyocytes
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:03:07 GMT 2023
Edited
by admin
on Sat Dec 16 17:03:07 GMT 2023
Record UNII
RUM6K67ESG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TREPROSTINIL
INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
RUMODOLIN
Brand Name English
LRX-15
Code English
TREPROSTINIL PHOSPHATE [USAN]
Common Name English
TREPROSTINIL [USAN]
Common Name English
L606
Code English
treprostinil [INN]
Common Name English
TREPROSTINIL [JAN]
Common Name English
L-606
Code English
[(1R,2R,3aS,9aS)-2-Hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent[b]naphthalen-5-yl]oxy]acetate
Common Name English
TYVASO
Brand Name English
REMODULIN
Brand Name English
15-AU-81
Code English
TREPROSTINIL [ORANGE BOOK]
Common Name English
TREPROSTINIL [MART.]
Common Name English
Treprostinil [WHO-DD]
Common Name English
UT-15
Code English
TREPROSTINIL [VANDF]
Common Name English
UNIPROST
Brand Name English
15AU81
Code English
TREPROSTINIL [MI]
Common Name English
ACETIC ACID,(((1R,2R,3AS,9AS)-2,3,3A,4,9,9A-HEXAHYDRO-2-HYDROXY-1-((3S)-3-HYDROXYOCTYL)-1H-BENZ(F)INDEN-5-YL)OXY)-
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 189104
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
WHO-ATC B01AC21
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
NDF-RT N0000011280
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
NCI_THESAURUS C78568
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
LIVERTOX 992
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
NCI_THESAURUS C29707
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
FDA ORPHAN DRUG 105197
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
FDA ORPHAN DRUG 711319
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
NDF-RT N0000009909
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
NDF-RT N0000011280
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
WHO-VATC QB01AC21
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
NDF-RT N0000011280
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
FDA ORPHAN DRUG 787620
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
NDF-RT N0000175416
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
Code System Code Type Description
LACTMED
Treprostinil
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
INN
8170
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
MERCK INDEX
m11018
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY Merck Index
CHEBI
50863
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID901021654
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
IUPHAR
5820
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
DRUG CENTRAL
2720
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
RXCUI
343048
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY RxNorm
FDA UNII
RUM6K67ESG
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
DAILYMED
RUM6K67ESG
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
EVMPD
SUB21168
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
PUBCHEM
6918140
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
CAS
81846-19-7
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
NCI_THESAURUS
C61983
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
WIKIPEDIA
TREPROSTINIL
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
USAN
MM-25
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
DRUG BANK
DB00374
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
SMS_ID
100000092046
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
ChEMBL
CHEMBL1237119
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
CHEBI
50861
Created by admin on Sat Dec 16 17:03:09 GMT 2023 , Edited by admin on Sat Dec 16 17:03:09 GMT 2023
PRIMARY
Related Record Type Details
Structure of TREPROSTINIL DIOLAMINE
SALT/SOLVATE -> PARENT
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA
TARGET -> AGONIST
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
P2Y PURINOCEPTOR 12
TARGET -> AGONIST
PROSTACYCLIN RECEPTOR
TARGET -> AGONIST
Structure of TREPROSTINIL
EXCRETED UNCHANGED
URINE
Structure of TREPROSTINIL SODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of Treprostinil Phosphate
PRODRUG -> METABOLITE ACTIVE
Structure of 3-((1R,2R,3AS,9AS)-5-(CARBOXYMETHYLOXY)-2-HYDROXY-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYCLOPENTA(B)NAPHTHALEN-1-YL)-3-OXO-PROPANOIC ACID
METABOLITE -> PARENT
URINE
Structure of TREPROSTINIL PALMITIL
PRODRUG -> METABOLITE ACTIVE
Structure of (2S,3S,4S,5R,6S)-6-(2-(((1R,2R,3AS,9AS)-2-HYDROXY-1-((3S)-3-HYDROXYOCTYL)-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYCLOPENTA(G)NAPHTHALEN-5-YL)OXY)ACETYL)OXY-3,4,5-TRIHYDROXY-TETRAHYDROPYRAN-2-CARBOXYLIC ACID
METABOLITE -> PARENT
URINE
Structure of 6-((1R,2R,3AS,9AS)-5-(CARBOXYMETHOXY)-2-HYDROXY-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYCLOPENTA(B)NAPHTHALEN-1-YL)HEX-3-ENOIC ACID, (E)-
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of 3-((1R,2R,3AS,9AS)-5-(CARBOXYMETHYLOXY)-2-HYDROXY-2,3,3A,4,9,9A-HEXAHYDRO-1H-CYCLOPENTA(B)NAPHTHALEN-1-YL)PROPANOIC ACID
IMPURITY -> PARENT
URINE
Related Record Type Details
Structure of TREPROSTINIL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966